Mesothelioma and radical multimodality therapy: who benefits?

Chest. 1995 Jun;107(6 Suppl):345S-350S. doi: 10.1378/chest.107.6_supplement.345s.

Abstract

The incidence of malignant pleural mesothelioma is increasing. Untreated, patients with this disease experience a rapid and horrendous clinical decline. Surgery plays a role in the diagnosis, staging, and treatment of this malignancy. Surgery, chemotherapy, and radiotherapy alone have been unable to achieve major improvements in survival for most patients. More recent phase II trials suggest that surgery, at one time a purely palliative approach, may have a potentially curative role when used in combination with chemotherapy and radiotherapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Humans
  • Mesothelioma / drug therapy
  • Mesothelioma / mortality
  • Mesothelioma / radiotherapy
  • Mesothelioma / surgery*
  • Pleural Neoplasms / drug therapy
  • Pleural Neoplasms / mortality
  • Pleural Neoplasms / radiotherapy
  • Pleural Neoplasms / surgery*
  • Pneumonectomy
  • Radiotherapy, Adjuvant
  • Survival Rate

Substances

  • Antineoplastic Agents